anti human vascular endothelial growth factor c vegf c goat polyclonal ab  (R&D Systems)

Journal: Microorganisms

Article Title: Molecular Basis of The Retinal Pigment Epithelial Changes That Characterize The Ocular Lesion in Toxoplasmosis

doi: 10.3390/microorganisms7100405

Figure Lengend Snippet: Expression of growth factors by human retinal pigment epithelial cells infected with GT-1 strain T. gondii tachyzoites (multiplicity of infection = 5; evaluated time points post-infection = 4 and 24 h). Graphs showing normalized transcript expression for selected growth factors in ( A ) infected versus uninfected ARPE-19 cells (representative of results obtained in at least two of three independent experiments) or ( B ) two infected versus uninfected primary cell isolates. Reference genes were ribosomal protein lateral stalk subunit P0 (RPLP0) and peptidylprolyl isomerase A (PPIA). Data were analyzed by two-tailed Student’s t -test. n = 6 cultures/condition. Bars represent mean normalized expression, and error bars indicate standard error of the mean. VEGF = vascular endothelial growth factor A; VEGFB = vascular endothelial growth factor B; EGF = epidermal growth factor; IGF1 = insulin-like growth factor 1; FGF2 = fibroblast growth factor 2; TSP1 = thrombospondin 1. * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001.

Article Snippet: Rabbit polyclonal anti-human antigen KI-67 (KI-67) antibody was sourced from Abcam (Cambridge, U.K.), and goat polyclonal anti-human vascular endothelial growth factor A (VEGF) antibody and goat polyclonal anti-human insulin-like growth factor 1 (IGF1) antibody were sourced from R&D Systems (Minneapolis, MN, USA).

Techniques: Expressing, Infection, Two Tailed Test

Journal: Microorganisms

Article Title: Molecular Basis of The Retinal Pigment Epithelial Changes That Characterize The Ocular Lesion in Toxoplasmosis

doi: 10.3390/microorganisms7100405

Figure Lengend Snippet: Secretion of growth factors by human retinal pigment epithelial cells infected with GT-1 strain T. gondii tachyzoites (multiplicity of infection = 5; evaluated time point post-infection = 24 h), and impact of antibody blockade or protein supplementation on antigen KI-67 (KI-67) expression by conditioned cells. ( A ) Graphs showing protein concentration in supernatant collected from infected versus uninfected ARPE-19 cells, as measured by enzyme-linked immunosorbent assay. Data were analyzed by two-tailed Student’s t -test. n = 6 cultures/condition. ( B ) Graphs of fold-difference in KI-67 immunolabelling, measured in photomicrographs from ARPE-19 cells exposed for 24 h to conditioned medium collected from T. gondii -infected (TgCM) or uninfected (CM) ARPE-19 cells, and ( B ) blocked with antibodies directed against human VEGF (5 µg/mL) and/or IGF1 (15 µg/mL) or negative control immunoglobulin (IgG), or ( C ) supplemented with human TSP1 (0.5–2.0 µg/mL) (representative of two independent experiments). Data were analyzed by ( B ) two-tailed Student’s t -test or ( C ) one-way ANOVA. n = 12 photomicrographs/condition. Bars represent ( A ) mean secretion or ( B and C ) fold-difference, and error bars indicated standard error of the mean. VEGF = vascular endothelial growth factor A; IGF1 = insulin-like growth factor 1; TSP1 = thrombospondin 1. * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001. In ( C ) different letters denote significant differences.

Article Snippet: Rabbit polyclonal anti-human antigen KI-67 (KI-67) antibody was sourced from Abcam (Cambridge, U.K.), and goat polyclonal anti-human vascular endothelial growth factor A (VEGF) antibody and goat polyclonal anti-human insulin-like growth factor 1 (IGF1) antibody were sourced from R&D Systems (Minneapolis, MN, USA).

Techniques: Infection, Expressing, Protein Concentration, Enzyme-linked Immunosorbent Assay, Two Tailed Test, Negative Control

Journal: Oncology Letters

Article Title: Thymoquinone chemosensitizes colon cancer cells through inhibition of NF-κB

doi: 10.3892/ol.2016.4971

Figure Lengend Snippet: TQ inhibits the activation of NF-κB and downregulates its downstream gene expression. (A) TQ inhibited phosphorylation of the subunit of NF-κB, p65. COLO205 cells were treated with 60 µM TQ for 18 h. Cells were harvested and the expression of phosphorylated p65 in the nucleus was evaluated by western blot analysis. β-actin was used as an internal control. A representative blot of three experiments with similar results is shown. (B) TQ downregulated NF-κB downstream gene products in COLO205 cells. Following 18 h of incubation, the levels of VEGF, c-Myc and Bcl-2 were determined by western blot analysis. β-actin was used as an internal control. A representative blot of three experiments with similar results is shown. TQ, thymoquinone; NF-κB, nuclear factor-κB; VEGF, vascular endothelial growth factor; Bcl-2, B-cell lymphoma 2.

Article Snippet: Primary antibodies, including rabbit polyclonal anti-human p65 (catalog no., sc-101749; 1:500), rabbit polyclonal anti-human B-cell lymphoma 2 (Bcl-2; catalog no., sc-492; 1:2,000), rabbit polyclonal anti-human vascular endothelial growth factor (VEGF; catalog no., sc-507; 1:1,000), mouse polyclonal anti-human c-Myc (catalog no., sc-40: 1:500), and secondary antibodies, including goat anti-rabbit horseradish peroxidase (HRP)-conjugated (catalog no., sc-2054: 1:10,000) and goat anti-mouse HRP-conjugated (catalog no., sc-2005 1:10,000) were obtained from Santa Cruz Biotechnology, Inc. (Dallas, TX, USA).

Techniques: Activation Assay, Gene Expression, Phospho-proteomics, Expressing, Western Blot, Control, Incubation

Journal: Molecular Medicine Reports

Article Title: Hypoxia is important in F-18 FDG accumulation in thecoma-fibroma tumors on F-18 FDG PET/CT scans

doi: 10.3892/mmr.2016.5016

Figure Lengend Snippet: SUVmax (A) and immunohistochemical analysis findings of (B) GLUT1, (C) Ki-67, (D) LAT1, (E) HIF-1α and (F) VEGF expression in the imaged lesions. In the malignant ovarian tumors, HIF-1α, VEGF, LAT1, Ki-67, and GLUT1 expression tended to be relatively higher than that in the thecoma-fibroma group. In the F-18 FDG-positive thecoma-fibroma group, Ki-67 expression was low and LAT1 expression was absent, thereby excluding the possibility of malignancy in these lesions. However, considerable GLUT1, HIF-1α, and VEGF expression were observed. In the two cases of F-18 FDG-negative fibroma, HIF-1α, VEGF, LAT1, Ki-67 and GLUT1 expression levels were low or inconclusive. SUV, standard uptake value; GLUT1, glucose transporter 1; LAT1, L-type amino acid transporter 1; HIF-1α, hypoxia-inducible factor 1α; FDG, fluorodeoxyglucose.

Article Snippet: The following antibodies were used: Polyclonal rabbit anti-human glucose transporter 1 (GLUT1; 1:200 dilution; cat. no. ab15309; Abcam, Cambridge, UK), monoclonal mouse anti-human L-type amino acid transporter 1 (LAT-1; 1:50; clone LAT-1; cat. no. M7279; Dako, Glostrup, Denmark), monoclonal mouse anti-human hypoxia-inducible factor 1α (HIF-1α; 1:100; clone HIFa67; cat. no. MAB5382; Millipore, Billerica, MA, USA), polyclonal rabbit anti-human vascular endothelial growth factor (VEGF; 1:100; cat. no. A-20; Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA), and monoclonal mouse anti-human Ki-67 (1:100; clone MIB-1; cat. no. M7248; Dako).

Techniques: Immunohistochemical staining, Expressing

Journal: Biotechnology letters

Article Title: Ultrasensitive immuno-detection using viral nanoparticles with modular assembly using genetically-directed biotinylation

doi: 10.1007/s10529-014-1555-9

Figure Lengend Snippet: VEGF (26 aM - 2.6 pM) was spiked into 50% BAL fluid (in PBS), and incubated with polyclonal anti-VEGF antibody functionalized magnetic particles. The biotinylated antibody/Neutravidin/phage affinity reagent was added, followed by washing. The sample was then analyzed using real-time PCR with phage-specific primers (n=6, error bars = ±1 SD, Non-template control Ct ≥34). The No-VEGF control (Ct =22.67±0.55) is shown as a solid line with +/− one standard deviation represented by dotted lines.

Article Snippet: The particles were washed, resuspended in coating buffer (1×10 7 particles in 1 ml 0.1 M sodium borate, pH 9.5) and mixed with 240 μl polyclonal anti-human Vascular Endothelial Growth Factor (VEGF) antibody (1 mg/ml, AB-293-NA, R&D Systems) and 240 μl 3 M (NH 4 ) 2 SO 4 .

Techniques: Incubation, Real-time Polymerase Chain Reaction, Control, Standard Deviation